Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset sold 50,000 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $6.76, for a total value of $338,000.00. Following the transaction, the executive vice president now owns 462,956 shares in the company, valued at approximately $3,129,582.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Eliem Therapeutics Stock Performance

ELYM stock opened at $6.86 on Friday. Eliem Therapeutics, Inc. has a fifty-two week low of $2.35 and a fifty-two week high of $11.55. The business’s 50 day moving average price is $7.89 and its two-hundred day moving average price is $4.64. The company has a market capitalization of $204.09 million, a price-to-earnings ratio of -12.94 and a beta of -0.33.

Eliem Therapeutics (NASDAQ:ELYM) last posted its earnings results on Wednesday, May 15th. The company reported ($0.06) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Eliem Therapeutics stock. Cerity Partners LLC bought a new position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned 0.05% of Eliem Therapeutics as of its most recent filing with the Securities and Exchange Commission. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.